Meeting
2022 ASCO Annual Meeting
Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development.
Authors
Dazhi Liu
Memorial Sloan Kettering Cancer Center, New York, NY
Dazhi Liu , Yonina R. Murciano-Goroff , Justin Jee , Maria E. Arcila , Darren J. Buonocore , JianJiong Gao , Debyani Chakravarty , Alison M. Schram , Margaret K. Callahan , Claire Frances Friedman , Komal L. Jhaveri , James J. Harding , Mrinal M. Gounder , Ezra Rosen , Neal Rosen , Sandra Misale , Piro Lito , Rona Yaeger , Alexander E. Drilon , Bob T. Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3135)
DOI
10.1200/JCO.2022.40.16_suppl.3135
Abstract #
3135
Poster Bd #
127
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
Next-generation sequencing yields promising targets in advanced cholangiocarcinoma (CCA).
First Author: Rachna T. Shroff
Poster
2014 ASCO Annual Meeting
Comprehensive genomic profiling of gallbladder adenocarcinoma and frequent genomic-derived targets of therapy.
First Author: Phil Stephens
Poster
2022 ASCO Annual Meeting
Next-generation sequencing (NGS) for identifying actionable molecular alterations in patients with newly diagnosed and recurrent IDHwt-glioblastoma (GBM): A large mono-institutional experience.
First Author: Marta Padovan
Poster
2019 Gastrointestinal Cancers Symposium
Genomic alterations in appendiceal carcinoma using circulating DNA.
First Author: Walid Labib Shaib